Description
United Therapeutics Corporation: Expansion in Tyvaso To Build A Robust Foundation For Sustained Revenue!
United Therapeutics Corporation delivered a strong financial and developmental performance in the fourth quarter of 2024. The company reported a record-setting year for revenue, which marked the third consecutive year of such accomplishment. This performance was anchored by the robust growth of its treprostinil-based therapies, including Tyvaso, Orenitram, and Unituxin. Each of these products marked a double-digit growth in revenue, contributing to an overall 24% increase over the full year 2023.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
